Systemic amyloidosis-induced nail dystrophy

J Dtsch Dermatol Ges. 2019 Oct;17(10):1057-1059. doi: 10.1111/ddg.13942. Epub 2019 Sep 20.

Authors

Gwanghyun Jo¹, Dong-Yeop Shin^{2

3}, Je-Ho Mun^{1

4}

Affiliations

¹ Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea.
² Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital.
³ Center for Medical Innovation, Seoul National University Hospital Biomedical Research Institute, Seoul, Republic of Korea.
⁴ Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Republic of Korea.

PMID: 31538714
DOI: 10.1111/ddg.13942

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / therapeutic use
Biopsy, Needle / methods
Dermoscopy / methods
Dexamethasone / administration & dosage
Dexamethasone / therapeutic use
Drug Therapy, Combination
Female
Humans
Immunoglobulin Light-chain Amyloidosis / complications*
Immunoglobulin Light-chain Amyloidosis / drug therapy
Immunoglobulin Light-chain Amyloidosis / metabolism
Immunoglobulin lambda-Chains / metabolism
Immunohistochemistry / methods
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / therapeutic use
Middle Aged
Nail Diseases / diagnostic imaging
Nail Diseases / etiology*
Nail Diseases / pathology*
Thalidomide / administration & dosage
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents
Immunoglobulin lambda-Chains
Immunosuppressive Agents
Thalidomide
Dexamethasone